HOME >> MEDICINE >> NEWS
Treatments for prostate cancer may affect employment

Prostate cancer and its treatment may affect short-term employment status, and debilitating effects from the treatment may impede some job-related tasks, reports a new study in the July 6 issue of the Journal of the National Cancer Institute.

As more organizations recommend screening younger men for prostate cancer, the profile of prostate cancer patients is likely to shift from men older than 65 years to younger men who are more likely to still be in the work force. Treatments for prostate cancer can involve a number of complications, including incontinence, fatigue, or sexual dysfunction, many of which may interfere with work productivity.

To determine the influence of cancer treatment on employment, Cathy J. Bradley, Ph.D., of the Massey Cancer Center at Virginia Commonwealth University in Richmond, and colleagues tracked 267 men with prostate cancer who were employed at the start of the study. They asked the patients about their employment situation 3 months prior to receiving their diagnosis of cancer, and at 6 and 12 months after the diagnosis. They compared the results with those from two control groups of men without prostate cancer selected from U.S. Census population surveys.

The authors found that men with prostate cancer were 10% less likely to be working 6 months after their cancer diagnosis than men without the disease. However, approximately two-thirds of the patients still working said that they continued working out of fear of losing health insurance coverage. The authors note that this fear may have encouraged some who otherwise would have quit to keep working, which may have suppressed unemployment numbers. Additionally, those still working had decreased their weekly hours work by 4 hours on average, and 43% of them attributed their inability to work at their former capacity to cancer treatment-related symptoms.

After 12 months, the gap in employment status disappeared. However, some men with can
'"/>

Contact: Sarah L. Zielinski
jncimedia@oupjournals.org
301-841-1287
Journal of the National Cancer Institute
5-Jul-2005


Page: 1 2

Related medicine news :

1. Conventional prognostic factors fail to explain better prostate cancer survival in most Asian men
2. Trial shows circulating tumor cells predict how prostate cancer patients do with chemotherapy
3. African-American men understimate risk of prostate cancer
4. Treatment for early prostate cancer associated with type of specialist seen
5. Nonhormonal drug reduces hot flashes in men treated for prostate cancer
6. Flaxseed stunts the growth of prostate tumors
7. OHSU Cancer Institute shows findings of immunotherapy vaccine in prostate cancer patients
8. Radium-223: An alternative treatment for prostate cancer
9. OHSU Cancer Institute researcher identifies protein marker for prostate cancer survival
10. New prostate cancer clinical guidelines to be released
11. Data on new vaccine for prostate cancer to be presented

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Treatments for prostate cancer may affect employment

(Date:5/22/2013)... May 22, 2013 Digital Advertising Agency, ... behalf of its social media management client, Primal ... year's supply of the all-natural organic deodorant. The contest ... of the rapidly-growing start-up deodorant company based in Tampa, ... contest or sweepstakes on a Facebook page is a ...
(Date:5/22/2013)... NJ) John Theurer Cancer Center at Hackensack University Medical ... will bring together leading cancer experts, for presentation and ... therapy and interventional immunology in oncology, on Friday, June ... to bring together some of the nation,s top immunology ... cell therapies in oncology, both in solid and liquid ...
(Date:5/22/2013)... DiscountFurnaceFilter.com now offers a vast selection ... filters, dehumidifiers, fans, aroma diffusers, dehumidifiers and more. ... Form's product line to their selection! Stadler Form ... diffusers and dehumidifiers) to accentuate anyone’s home décor. ... perfect combination of design and functionality. Otto is ...
(Date:5/22/2013)... Garcinia cambogia select is a dual action ... the extra fat being stored in the body. For a ... This fat burner helps people in this regard by making ... Basically it does this by secreting a hormone serotonin which ... away from emotional overeating. In this way, it keeps a ...
(Date:5/22/2013)... NY (PRWEB) May 22, 2013 ... and Rensselaer Polytechnic Institute today announced an affiliation ... development of new diagnostic tools and treatments that ... a signing ceremony on May 22, 2013. , ... expertise—Rensselaer’s in engineering and invention prototyping and Mount ...
Breaking Medicine News(10 mins):Health News:Social Media Management Firm, 21Digital, Launches National Facebook Sweepstakes for Client, Primal Pit Paste 2Health News:Progress after recent breakthrough which opened new chapter in anti-cancer cell therapies 2Health News:DiscountFurnaceFilter.com Now Offers Stadler Form Products - Providing Solutions to All Your Summer Needs 2Health News:Garcinia Cambogia Reviews Released Online for Fast Weight Loss Solution with Offer of Extra 3 Month Supply 2Health News:Icahn School of Medicine at Mount Sinai and Rensselaer Polytechnic Institute Announce Academic Collaboration 2Health News:Icahn School of Medicine at Mount Sinai and Rensselaer Polytechnic Institute Announce Academic Collaboration 3Health News:Icahn School of Medicine at Mount Sinai and Rensselaer Polytechnic Institute Announce Academic Collaboration 4Health News:Icahn School of Medicine at Mount Sinai and Rensselaer Polytechnic Institute Announce Academic Collaboration 5Health News:Icahn School of Medicine at Mount Sinai and Rensselaer Polytechnic Institute Announce Academic Collaboration 6Health News:Icahn School of Medicine at Mount Sinai and Rensselaer Polytechnic Institute Announce Academic Collaboration 7
(Date:5/22/2013)... and TORONTO , May ... (OTCBB: GNBT) today announced three presentations demonstrating the superiority ... its wholly-owned subsidiary, Antigen Express, Inc. ( www.antigenexpress.com ). ... of the American Society of Clinical Oncology (ASCO) to ... May 31 through June 4, 2013. The ...
(Date:5/22/2013)... Mai 2013  Grifols, ein globales Unternehmen ... Barcelona , Spanien, präsentierte die Ergebnisse ... Dosis von PROLASTIN©-C (Alpha1-Proteinasehemmer [human]) den Spiegel ... auf ein Niveau anhebt, das innerhalb des ... ATT-Mangel ist eine lebensbedrohliche, genetische Erkrankung, bei ...
(Date:5/22/2013)... , May 22, 2013  Medifocus, Inc. (OTCQX: MDFZF and ... , Chief Operating Officer, will present at the Second Annual ... New York City at the Grand ... to begin at 4:00 p.m. EDT and will be available ...   http://wsw.com/webcast/marcum/mfs.v/   For more information and registration, ...
Breaking Medicine Technology:Generex Announces ASCO Presentations on the Antigen Express Advanced Stage AE37 Cancer Vaccine 2Generex Announces ASCO Presentations on the Antigen Express Advanced Stage AE37 Cancer Vaccine 3Generex Announces ASCO Presentations on the Antigen Express Advanced Stage AE37 Cancer Vaccine 4Studie von Grifols zeigt, dass eine höhere Dosis von PROLASTIN-C den Alpha1-PI-Spiegel in Patienten mit AAT-Mangel in den normalen Bereich anhebt 2Studie von Grifols zeigt, dass eine höhere Dosis von PROLASTIN-C den Alpha1-PI-Spiegel in Patienten mit AAT-Mangel in den normalen Bereich anhebt 3Studie von Grifols zeigt, dass eine höhere Dosis von PROLASTIN-C den Alpha1-PI-Spiegel in Patienten mit AAT-Mangel in den normalen Bereich anhebt 4Medifocus, Inc. to Present At The Second Annual Marcum LLP MicroCap Conference 2Medifocus, Inc. to Present At The Second Annual Marcum LLP MicroCap Conference 3
Cached News: